uncategorized

Arzanya and leadXpro collaborate on exploring macrocycle discovery on membrane proteins

Venice, Italy, and Villigen, Switzerland, 29 May 2026 Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets. The collaboration will combine Arzanya’s high-throughput yeast display screening platform for the selection of peptide macrocycles with leadXpro’s expertise in membrane protein generation, structure determination and application of biophysical methods to investigate the potential for discovering novel ligands against challenging membrane protein drug targets. Michael Hennig, leadXpro: “We’re excited to complement […]

Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins

Cambridge, UK, Boston MA, USA and Villigen, Switzerland, 17 February 2026. Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery’s™ rapid multiplex membrane protein screening with leadXpro’s AI/ML-driven construct design and membrane […]

Partex.AI and leadXpro announce collaboration to expand indications and support out-licensing of A2BR antagonist program

Eschborn, Germany and Villigen, Switzerland — 27/01/2026 — Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, and leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of leadXpro’s adenosine A2B receptor (A2BR) […]

New collaboration between leadXpro and Orbion!

Membrane proteins serve as a cell’s vital link to its external environment and play crucial roles in both health and disease. Although they make up only about a quarter of the human proteome, they are the targets of more than half of all approved drugs. However, studying these proteins in the lab is challenging due […]

leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery.

By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs

Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project

Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]

Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators

Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in […]